Diseño de análogos enantiopuros del fármaco antidepresivo y coadyuvante para el abandono del hábito de fumar: bupropión, por una metodología organocatalítica

Abstract

Since ancient times, medicines have been used to heal wounds, cure infections and other diseases. The huge use of all types of drugs involved serious side effects such as the case of the drug "thalidomide" that caused congenital (teratogenic) deformities in babies of mothers who had taken this drug during the first three months of pregnancy. Nowadays it is known that many of the commercialized drugs are racemic mixtures, which one of the enantiomers can have a more powerful effect and with less adverse effects than the other. Now the industry is looking for the rate of drugs marketed as racemic mixtures, and thus improve the quality of life of society by avoiding so that the incidents that fall depends on them. The aim of this project is to develop an organocatalitic method to obtain, in an enantiomerically pure manner, the analogs of Bupropion, a drug commercialized in a racemic way that works as an antidepressant and adjuvant for the cessation of smoking.